Parexel Supports Manufacturers With COVID-19 Risk Mitigation Offering

May 11, 2020

Applied Clinical Trials

Parexel has unveiled its COVID-19 Risk Mitigation offering, so that manufacturers can safely and confidently continue operations through the COVID-19 pandemic. Parexel’s regulatory experts will partner with life sciences companies aiming to ensure business continuity during these challenging times by analyzing manufacturing operations to reduce the risk of viral contamination. This will be accomplished through a four-step methodology. 

For more information, click here.

Related Content:

News